• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.原发 4T1 肿瘤切除为免疫治疗提供了关键的“机会窗口”。
Clin Exp Metastasis. 2014 Feb;31(2):185-98. doi: 10.1007/s10585-013-9619-0. Epub 2013 Oct 6.
2
Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.靶向髓源抑制性细胞联合原发性乳腺肿瘤切除术可减少肺部转移生长。
Breast Cancer Res. 2019 Sep 5;21(1):103. doi: 10.1186/s13058-019-1189-x.
3
Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy.通过化疗或免疫疗法治愈原发性/转移性EMT6或4THM乳腺癌的小鼠的免疫比较。
PLoS One. 2014 Nov 19;9(11):e113597. doi: 10.1371/journal.pone.0113597. eCollection 2014.
4
Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer.以一种新型药用级植物源激动剂Immunomax®靶向Toll样受体4(TLR-4),作为转移性乳腺癌的一种治疗策略。
J Transl Med. 2014 Nov 29;12:322. doi: 10.1186/s12967-014-0322-y.
5
Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.使用血管生成受体酪氨酸激酶抑制剂SU6668和免疫刺激剂B7.2-IgG融合蛋白对小鼠局部和转移性4T1乳腺肿瘤进行联合治疗。
Cancer Res. 2002 Oct 15;62(20):5727-35.
6
Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor.瘤内注射编码CC趋化因子配体16的腺病毒可抑制乳腺肿瘤生长,并在手术切除经治疗的原发性肿瘤后预防转移诱导的死亡。
J Immunol. 2004 Apr 1;172(7):4026-36. doi: 10.4049/jimmunol.172.7.4026.
7
Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden.切除原发肿瘤可通过降低总体肿瘤负担来改善转移性乳腺癌患者的生存。
Surgery. 2013 Jun;153(6):771-8. doi: 10.1016/j.surg.2013.02.002. Epub 2013 Mar 13.
8
Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model.沉默树突状细胞中的 IDO:一种增强乳腺癌模型中癌症免疫治疗的新方法。
Int J Cancer. 2013 Feb 15;132(4):967-77. doi: 10.1002/ijc.27710. Epub 2012 Jul 20.
9
Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.将MHC II类/CD80+肿瘤细胞与白细胞介素-12相结合的疫苗免疫疗法可减少已形成的转移性疾病,并刺激免疫效应细胞和干扰素γ诱导的单核因子。
Cancer Immunol Immunother. 2000 Apr;49(1):34-45. doi: 10.1007/s002620050024.
10
Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model.趋化因子Mig(CXCL9)在小鼠模型中对乳腺癌生长和转移的免疫介导调节作用
J Immunother. 2007 Jul-Aug;30(5):490-8. doi: 10.1097/CJI.0b013e318031b551.

引用本文的文献

1
Therapeutic limitations of oncolytic VSVd51-mediated miR-199a-5p delivery in triple negative breast cancer models.溶瘤性水疱性口炎病毒d51介导的miR-199a-5p递送在三阴性乳腺癌模型中的治疗局限性
Sci Rep. 2025 May 13;15(1):16634. doi: 10.1038/s41598-025-01584-0.
2
Noncovalently particle-anchored cytokines with prolonged tumor retention safely elicit potent antitumor immunity.非共价结合的、能延长肿瘤保留时间的细胞因子,可安全地引发有效的抗肿瘤免疫。
Sci Adv. 2024 Apr 19;10(16):eadk7695. doi: 10.1126/sciadv.adk7695.
3
Complete tumor resection reverses neutrophilia-associated suppression of systemic anti-tumor immunity.完整的肿瘤切除可逆转中性粒细胞增多相关的全身抗肿瘤免疫抑制。
Oral Oncol. 2024 Mar;150:106705. doi: 10.1016/j.oraloncology.2024.106705. Epub 2024 Jan 26.
4
MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target.乳腺癌中的 MDSCs:肿瘤进展的重要促进因素和新兴治疗靶点。
Front Immunol. 2023 Jul 3;14:1199273. doi: 10.3389/fimmu.2023.1199273. eCollection 2023.
5
Blood Stasis Syndrome Accelerates the Growth and Metastasis of Breast Cancer by Promoting Hypoxia and Immunosuppressive Microenvironment in Mice.血瘀证通过促进小鼠缺氧和免疫抑制微环境加速乳腺癌的生长和转移。
J Immunol Res. 2022 Jun 7;2022:7222638. doi: 10.1155/2022/7222638. eCollection 2022.
6
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models.癌症模型中的免疫巨环境的系统功能障碍和可塑性。
Nat Med. 2020 Jul;26(7):1125-1134. doi: 10.1038/s41591-020-0892-6. Epub 2020 May 25.
7
Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.靶向髓源抑制性细胞联合原发性乳腺肿瘤切除术可减少肺部转移生长。
Breast Cancer Res. 2019 Sep 5;21(1):103. doi: 10.1186/s13058-019-1189-x.
8
Phenotypic and transcriptomic characterization of canine myeloid-derived suppressor cells.犬髓系来源抑制细胞的表型和转录组学特征。
Sci Rep. 2019 Mar 5;9(1):3574. doi: 10.1038/s41598-019-40285-3.
9
Long-chain omega-3 polyunsaturated fatty acids decrease mammary tumor growth, multiorgan metastasis and enhance survival.长链 ω-3 多不饱和脂肪酸可降低乳腺肿瘤生长、多器官转移并提高存活率。
Clin Exp Metastasis. 2018 Dec;35(8):797-818. doi: 10.1007/s10585-018-9941-7. Epub 2018 Oct 16.
10
Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas.肿瘤切除招募效应 T 细胞,并增强表达 IFNβ 的封装干细胞在胶质母细胞瘤中的治疗效果。
Clin Cancer Res. 2017 Nov 15;23(22):7047-7058. doi: 10.1158/1078-0432.CCR-17-0077. Epub 2017 Sep 14.

本文引用的文献

1
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.抗 PD-1 和 B7-H1(PD-L1)抗体在治疗晚期人类癌症中的应用。
Clin Cancer Res. 2013 Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063.
2
Tremelimumab: a review of development to date in solid tumors. Tremelimumab:至今在实体瘤方面的开发进展综述。
Immunotherapy. 2013 Mar;5(3):215-29. doi: 10.2217/imt.13.9.
3
Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.髓源性抑制细胞通过 IDO 表达抑制抗肿瘤免疫反应,并与乳腺癌患者的淋巴结转移相关。
J Immunol. 2013 Apr 1;190(7):3783-97. doi: 10.4049/jimmunol.1201449. Epub 2013 Feb 25.
4
Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC.在接受新辅助化疗(NAC)和手术的大体积局部晚期乳腺癌女性中存在异常调节性 T 细胞(Tregs:FOXP3+,CTLA-4+)、髓系来源抑制细胞(MDSCs:单核细胞、粒细胞)和极化 T 辅助细胞表型(Th1、Th2、Th17):治疗未能消除异常 Treg 表型,Treg 水平与 NAC 病理反应相关。
J Transl Med. 2013 Jan 15;11:16. doi: 10.1186/1479-5876-11-16.
5
MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.用于结直肠高级腺瘤患者的 MUC1 疫苗:癌症免疫预防可行性研究。
Cancer Prev Res (Phila). 2013 Jan;6(1):18-26. doi: 10.1158/1940-6207.CAPR-12-0275. Epub 2012 Dec 17.
6
[Myeloid-derived suppressor cells in patients with breast cancer].[乳腺癌患者中的髓源性抑制细胞]
Gan To Kagaku Ryoho. 2012 Sep;39(9):1363-8.
7
Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer.循环髓系来源的抑制性细胞增加,并与癌症患者的免疫抑制、炎症和低蛋白血症相关。
Oncol Rep. 2012 Aug;28(2):453-8. doi: 10.3892/or.2012.1812. Epub 2012 May 14.
8
Drug development: Raise standards for preclinical cancer research.药物研发:提高临床前癌症研究标准。
Nature. 2012 Mar 28;483(7391):531-3. doi: 10.1038/483531a.
9
Coordinated regulation of myeloid cells by tumours.肿瘤对髓系细胞的协调调控。
Nat Rev Immunol. 2012 Mar 22;12(4):253-68. doi: 10.1038/nri3175.
10
Myeloid-derived suppressor cells in cancer patients: a clinical perspective.癌症患者中的髓源性抑制细胞:临床视角。
J Immunother. 2012 Feb-Mar;35(2):107-15. doi: 10.1097/CJI.0b013e318242169f.

原发 4T1 肿瘤切除为免疫治疗提供了关键的“机会窗口”。

Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.

机构信息

Department of Molecular Immunology, Institute for Molecular Medicine, 16371 Gothard Street, Suite H, Huntington Beach, CA, 92647, USA,

出版信息

Clin Exp Metastasis. 2014 Feb;31(2):185-98. doi: 10.1007/s10585-013-9619-0. Epub 2013 Oct 6.

DOI:10.1007/s10585-013-9619-0
PMID:24096737
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3946940/
Abstract

It is believed that primary tumor resection modulates host-tumor immune interaction, but this has not been characterized in a stringent breast cancer tumor model. This report, using the 4T1 murine mammary tumor model, characterizes for the first time the dynamic longitudinal changes in immunosuppressive and effector components of the immune system after resection of an established orthotopic primary tumor with a defined natural history of developing lung metastases. More specifically, we analyzed changes of absolute numbers and frequencies of MDSC, regulatory T cells (Treg), as well as activated CD4 and CD8 positive T cells in spleens and, in some studies, lungs of 4T1 tumor-bearing mice and mice after primary tumor resection. Importantly, using mathematical analyses we established that primary resection of an orthotopic tumor had created a "window of opportunity" with decreased tumor-associated immune suppression that existed for approximately 10 days. Although tumor resection did slightly prolong survival, it did not affect the ultimate development of metastatic disease since animals with resected tumors or intact primary tumors eventually died by day 47 and 43, respectively. This window of opportunity likely occurs in humans providing a rationale and parameters for integration and testing of immunotherapeutic strategies in this critical "window of opportunity" to combat the development of metastatic disease.

摘要

人们认为原发肿瘤切除术可以调节宿主-肿瘤免疫相互作用,但这在严格的乳腺癌肿瘤模型中尚未得到证实。本报告首次使用 4T1 鼠乳腺肿瘤模型,描述了在具有明确发生肺转移自然史的原位原发性肿瘤切除后,免疫系统中免疫抑制和效应成分的动态纵向变化。更具体地说,我们分析了在原发性肿瘤切除后,4T1 荷瘤小鼠和小鼠的脾脏中髓源性抑制细胞(MDSC)、调节性 T 细胞(Treg)以及活化的 CD4 和 CD8 阳性 T 细胞的绝对数量和频率的变化,在一些研究中还分析了肺部的变化。重要的是,我们通过数学分析确定,原发性肿瘤切除术创造了一个“机会之窗”,在此期间肿瘤相关免疫抑制降低,大约持续 10 天。尽管肿瘤切除术略微延长了生存时间,但它并没有影响转移性疾病的最终发展,因为接受肿瘤切除术或完整原发性肿瘤的动物最终分别在第 47 天和第 43 天死亡。这个机会之窗可能在人类中存在,为在这个关键的“机会之窗”中整合和测试免疫治疗策略提供了理由和参数,以对抗转移性疾病的发展。